SG10202100326SA - Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers - Google Patents

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Info

Publication number: SG10202100326SA
Authority: SG; Singapore
Prior art keywords: peptides; cancers; combination; immunotherapy against; against leukemias
Prior art date: 2017-04-10

Application number

SG10202100326SA

Inventor

Juliane Sarah Walz

Daniel Kowalewski

Markus Löffler

Marco Moreno Di

Nico Trautwein

Annika Nelde

Stefan Stevanovic

Hans-Georg Rammensee

Sebastian Haen

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-10

Filing date

2018-04-10

Publication date

2021-02-25

2018-04-10 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2021-02-25 Publication of SG10202100326SA publication Critical patent/SG10202100326SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Plant Pathology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)

SG10202100326SA 2017-04-10 2018-04-10 Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers SG10202100326SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762483690P	2017-04-10	2017-04-10
DE102017107710		2017-04-10

Publications (1)

Publication Number	Publication Date
SG10202100326SA true SG10202100326SA (en)	2021-02-25

Family

ID=62116820

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10202100326SA SG10202100326SA (en)	2017-04-10	2018-04-10	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
SG10202100324YA SG10202100324YA (en)	2017-04-10	2018-04-10	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
SG11201909058W SG11201909058WA (en)	2017-04-10	2018-04-10	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10202100324YA SG10202100324YA (en)	2017-04-10	2018-04-10	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
SG11201909058W SG11201909058WA (en)	2017-04-10	2018-04-10	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Country Status (18)

Country	Link
US (2)	US20220118016A1 (en)
EP (1)	EP3609531A2 (en)
JP (1)	JP7026970B2 (en)
KR (1)	KR20190137858A (en)
CN (3)	CN112521478A (en)
AU (1)	AU2018253341B2 (en)
BR (1)	BR112019021094A2 (en)
CA (1)	CA3059645A1 (en)
CL (7)	CL2019002878A1 (en)
CO (1)	CO2019012071A2 (en)
CR (1)	CR20190509A (en)
IL (1)	IL269813A (en)
MA (1)	MA49123A (en)
MX (1)	MX2019012226A (en)
MY (1)	MY197772A (en)
PE (1)	PE20191617A1 (en)
PH (1)	PH12019502300A1 (en)
SG (3)	SG10202100326SA (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3079707A4 (en) *	2013-12-02	2017-10-18	RXi Pharmaceuticals Corporation	Immunotherapy of cancer
MX2019008844A (en) *	2017-01-26	2019-09-10	Sangamo Therapeutics Inc	B-cell engineering.
EP4316597A3 (en) *	2017-07-07	2024-11-06	immatics biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
CN113109564A (en) *	2021-03-15	2021-07-13	成都益安博生物技术有限公司	Peripheral blood TCR marker of acute myelocytic leukemia and detection kit and application thereof
CN117586344A (en) *	2022-08-12	2024-02-23	上海交通大学医学院附属瑞金医院	Antigenic peptide targeting FLT3-D835 mutation and application thereof in tumor immunotherapy
CN117552115B (en) *	2024-01-12	2024-03-26	天津鲸鹏生物科技有限责任公司	Universal antigen peptide library for inducing tumor specific immune response and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040005561A1 (en) *	2000-03-01	2004-01-08	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030148321A1 (en)	2001-08-24	2003-08-07	Iris Pecker	Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en)	2002-11-14	2011-10-18	John Wayne Cancer Institute	Detection of cancer cells in body fluids
US20080020990A1 (en)	2003-05-30	2008-01-24	Nippon Shinyaku Co., Ltd.	Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same
EP2386854A1 (en)	2005-04-19	2011-11-16	Prediction Sciences LLC	Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en)	2005-07-15	2008-11-13	The Trustees Of Columbia University In The City Of	Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
PT1760088E (en)	2005-09-05	2008-05-14	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
US20090263832A1 (en) *	2005-11-30	2009-10-22	Roberto Polakiewicz	Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
WO2008103905A2 (en)	2007-02-23	2008-08-28	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Antibodies that specifically bind irta and methods of use
AU2008281013B2 (en) *	2007-07-27	2012-06-28	Immatics Biotechnologies Gmbh	Composition of tumour-associated peptides and related anti-cancer vaccine
GB0721686D0 (en) *	2007-11-05	2007-12-12	Medinnova As	Polypeptides
WO2010019921A2 (en)	2008-08-15	2010-02-18	The Regents Of The University Of California	Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2010106535A1 (en)	2009-03-15	2010-09-23	Technion Research And Development Foundation Ltd.	Soluble hla complexes for use in disease diagnosis
US20120178111A1 (en)	2009-09-23	2012-07-12	Diamandis Eleftherios P	Methods and compositions for the detection of lung cancers
WO2014180490A1 (en)	2013-05-10	2014-11-13	Biontech Ag	Predicting immunogenicity of t cell epitopes
TWI776192B (en) *	2013-08-05	2022-09-01	德商伊瑪提克斯生物科技有限公司	Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201511191D0 (en)	2015-06-25	2015-08-12	Immatics Biotechnologies Gmbh	T-cell epitopes for the immunotherapy of myeloma
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201521746D0 (en)	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en)	2015-12-11	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers

2018
- 2018-04-10 MY MYPI2019005841A patent/MY197772A/en unknown
- 2018-04-10 EP EP18722907.5A patent/EP3609531A2/en active Pending
- 2018-04-10 CN CN202011264405.8A patent/CN112521478A/en active Pending
- 2018-04-10 SG SG10202100326SA patent/SG10202100326SA/en unknown
- 2018-04-10 JP JP2020504441A patent/JP7026970B2/en active Active
- 2018-04-10 MA MA049123A patent/MA49123A/en unknown
- 2018-04-10 MX MX2019012226A patent/MX2019012226A/en unknown
- 2018-04-10 SG SG10202100324YA patent/SG10202100324YA/en unknown
- 2018-04-10 CR CR20190509A patent/CR20190509A/en unknown
- 2018-04-10 CN CN202010276749.4A patent/CN111533799A/en active Pending
- 2018-04-10 KR KR1020197032832A patent/KR20190137858A/en not_active Application Discontinuation
- 2018-04-10 PE PE2019001977A patent/PE20191617A1/en unknown
- 2018-04-10 CN CN201880023853.3A patent/CN110944660A/en active Pending
- 2018-04-10 CA CA3059645A patent/CA3059645A1/en active Pending
- 2018-04-10 BR BR112019021094-6A patent/BR112019021094A2/en not_active IP Right Cessation
- 2018-04-10 AU AU2018253341A patent/AU2018253341B2/en not_active Ceased
- 2018-04-10 SG SG11201909058W patent/SG11201909058WA/en unknown
2019
- 2019-10-03 IL IL26981319A patent/IL269813A/en unknown
- 2019-10-07 PH PH12019502300A patent/PH12019502300A1/en unknown
- 2019-10-09 CL CL2019002878A patent/CL2019002878A1/en unknown
- 2019-10-29 CO CONC2019/0012071A patent/CO2019012071A2/en unknown
2020
- 2020-11-13 CL CL2020002948A patent/CL2020002948A1/en unknown
- 2020-11-13 CL CL2020002952A patent/CL2020002952A1/en unknown
- 2020-11-13 CL CL2020002950A patent/CL2020002950A1/en unknown
- 2020-11-13 CL CL2020002949A patent/CL2020002949A1/en unknown
- 2020-11-13 CL CL2020002951A patent/CL2020002951A1/en unknown
- 2020-11-13 CL CL2020002953A patent/CL2020002953A1/en unknown
2021
- 2021-06-23 US US17/356,174 patent/US20220118016A1/en not_active Abandoned
2022
- 2022-06-17 US US17/843,412 patent/US11559550B2/en active Active

Also Published As

Publication number	Publication date
PH12019502300A1 (en)	2020-07-06
US20220118016A1 (en)	2022-04-21
CL2020002952A1 (en)	2021-02-26
CL2020002951A1 (en)	2021-02-26
MY197772A (en)	2023-07-13
CN111533799A (en)	2020-08-14
KR20190137858A (en)	2019-12-11
CL2020002953A1 (en)	2021-03-12
CO2019012071A2 (en)	2020-04-01
US20220362302A1 (en)	2022-11-17
MA49123A (en)	2020-03-25
CL2020002948A1 (en)	2021-02-26
AU2018253341B2 (en)	2022-01-13
SG10202100324YA (en)	2021-02-25
PE20191617A1 (en)	2019-11-05
JP7026970B2 (en)	2022-03-01
SG11201909058WA (en)	2019-10-30
CA3059645A1 (en)	2018-10-18
MX2019012226A (en)	2020-02-07
CN110944660A (en)	2020-03-31
JP2020516313A (en)	2020-06-11
IL269813A (en)	2019-11-28
CL2020002949A1 (en)	2021-02-26
BR112019021094A2 (en)	2020-05-12
US11559550B2 (en)	2023-01-24
AU2018253341A1 (en)	2019-11-14
EP3609531A2 (en)	2020-02-19
CN112521478A (en)	2021-03-19
CR20190509A (en)	2020-01-08
CL2019002878A1 (en)	2020-03-13
CL2020002950A1 (en)	2021-02-26

Publication	Publication Date	Title
HRP20210709T8 (en)	2022-03-18	Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202110292UA (en)	2021-10-28	Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG10202101368WA (en)	2021-03-30	Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201604458D0 (en)	2016-04-27	Peptides and combination of peptides for use in immunotherapy against cancers
ZA201801036B (en)	2018-12-19	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202005950XA (en)	2020-07-29	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201511792D0 (en)	2015-08-19	Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG10202001485UA (en)	2020-04-29	Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG11201706155XA (en)	2017-09-28	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
IL261786A (en)	2018-10-31	Peptides and combination of peptides for use in immunotherapy against cancers
IL269813A (en)	2019-11-28	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
IL269741A (en)	2019-11-28	Peptides and combination thereof for use in the immunotherapy against cancers
HK1246181A1 (en)	2018-09-07	Novel peptides and combination of peptides for use in immunotherapy against various tumors
HK1255541A1 (en)	2019-08-23	Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL280879A (en)	2021-04-29	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
IL262081A (en)	2018-11-29	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
ZA201805512B (en)	2019-06-26	Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers